Screener
Nuvectis Pharma, Inc. NVCT Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Nuvectis Pharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055318
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accrued liabilities | 36 | 115 |
| Employee compensation and benefits | 6,447 | 6,907 |
| TOTAL CURRENT LIABILITIES | 11,178 | 13,296 |
| TOTAL LIABILITIES | 11,178 | 13,296 |
| COMMITMENTS AND CONTINGENCIES, see Note 3 | ||
| SHAREHOLDERS’ EQUITY, see Note 4 | ||
| Common Shares, $0.00001 par value – 60,000,000 shares authorized as of March 31, 2026, and December 31, 2025, 26,525,533, and 25,676,798 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | * | * |
| Additional paid in capital | 119,957 | 118,100 |
Item 1. Financial Statements
FAQ
- What is Nuvectis Pharma, Inc.'s total liabilities?
- Nuvectis Pharma, Inc. (NVCT) reported total liabilities of $11.18M in Q1 2026.
- How has Nuvectis Pharma, Inc.'s total liabilities changed year-over-year?
- Nuvectis Pharma, Inc.'s total liabilities increased by 21.6% year-over-year, from $9.19M to $11.18M.
- What is the long-term trend for Nuvectis Pharma, Inc.'s total liabilities?
- Over 4 years (2021 to 2025), Nuvectis Pharma, Inc.'s total liabilities has grown at a 53.1% compound annual growth rate (CAGR), from $2.42M to $13.3M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Nuvectis Pharma, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude